SEARCH

SEARCH BY CITATION

References

  • 1
    Rowley, J. D. ( 1973) A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining. Nature 243, 290293.
  • 2
    Lugo, T. G., Pendergast, A. M., Muller, A. J., and Witte, O. N. ( 1990) Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247, 10791082.
  • 3
    Daley, G. Q., Van Etten, R. A., and Baltimore, D. ( 1990) Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247, 824830.
  • 4
    Kelliher, M. A., McLaughlin, J., Witte, O. N., and Rosenberg, N. ( 1990) Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc. Natl. Acad. Sci. USA 87, 66496653.
  • 5
    Kurzrock, R., Gutterman, J. U., and Talpaz, M. ( 1988) The molecular genetics of Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 319, 990998.
  • 6
    Ren, R. ( 2005) Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat. Rev. Cancer 5, 172183.
  • 7
    Bedi, A., Barber, J. P., Bedi, G. C., el-Deiry, W. S., Sidransky, D., et al. ( 1995) BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anti-cancer agents. Blood 86, 11481158.
  • 8
    Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., et al. ( 1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2, 561566.
  • 9
    IIImer, T., Schaich, M., Platzbecker, U., Freiberg-Richter, J., Oelschlägel, U., et al. ( 2004) P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 18, 401408.
  • 10
    Lyss, G., Knorre, A., Schmidt, T. J., Pahl, H. L., and Merfort, I. ( 1998) The anti-inflammatory sesquiterpene lactone helenalin inhibits the transcription factor NF-kappaB by directly targeting p65. J. Biol. Chem. 273, 3350833516.
  • 11
    Zhang, S., Won, Y. K., Ong, C. N., and Shen, H. M. ( 2005) Anti-cancer potential of sesquiterpene lactones: bioactivity and molecular mechanisms. Curr. Med. Chem. Anticancer Agents 5, 239249.
  • 12
    Ghantous, A., Gali-Muhtasib, H., Vuorela, H., Saliba, N. A., and Darwiche, N. ( 2010) What made sesquiterpene lactones reach cancer clinical trials? Drug Discov. Today 15, 668678.
  • 13
    Lei, J. C., Yu, J. Q., Yin, Y., Liu, Y. W., and Zou, G. L. ( 2012) Alantolactone induces activation of apoptosis in human hepatoma cells. Food Chem. Toxicol. 50, 33133319.
  • 14
    Khan, M., Yi, F., Rasul, A., Li, T., Wang, N., et al. ( 2012) Alantolactone induces apoptosis in glioblastoma cells via GSH depletion, ROS generation, and mitochondrial dysfunction. IUBMB Life 64, 783794.
  • 15
    Lawrence, N. J., McGown, A. T., Nduka, J., Hadfield, J. A., and Pritchard, R. G. ( 2001) Cytotoxic Michael-type amine adducts of alpha-methylene lactones alantolactone and isoalantolactone. Bioorg. Med. Chem. Lett. 11, 429431.
  • 16
    Pal, H. C., Sehar, I., Bhushan, S., Gupta, B. D., and Saxena, A. K. ( 2010) Activation of caspases and poly (ADP-ribose) polymerase cleavage to induce apoptosis in leukemia HL-60 cells by Inula racemosa. Toxicol. In Vitro 24, 15991609.
  • 17
    Dirsch, V. M., Stuppner, H., and Vollmar, A. M. ( 2001) Cytotoxic sesquiterpene lactones mediate their death-inducing effect in leukemia T cells by triggering apoptosis. Planta Med. 67, 557559.
  • 18
    Xiang, Q. F., Wang, F., Su, X. D., Liang, Y. J., Zheng, L. S., et al. ( 2011) Effect of BIBF 1120 on reversal of ABCB1-mediated multidrug resistance. Cell. Oncol(Dordr). 34, 3344.
  • 19
    Yu, C., Krystal, G., Varticovksi, L., McKinstry, R., Rahmani, M., et al. ( 2002) Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. Cancer Res. 62, 188199.
  • 20
    Bedi, A., Zehnbauer, B. A., Barber, J. P., Sharkis, S. J., and Jones, R. J. ( 1994) Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 83, 20382044.
  • 21
    McGahon, A., Bissonnette, R., Schmitt, M., Cotter, K. M., Green, D. R., et al. ( 1994) BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 83, 11791187.
  • 22
    Litman, T., Zeuthen, T., Skovsgaard, T., and Stein, W. D. ( 1997) Competitive, non-competitive and cooperative interactions between substrates of P-glycoprotein as measured by its ATPase activity. Biochim. Biophys. Acta 1361, 169176.
  • 23
    Gamet-Payrastre, L., Li, P., Lumeau, S., Cassar, G., Dupont, M. A., et al. ( 2000) Sulforaphane, a naturally occurring isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer cells. Cancer Res. 60, 14261433.
  • 24
    Murray, A. W. ( 2004) Recycling the cell cycle: cyclins revisited. Cell 116, 221234.
  • 25
    Lu, Y. J., Yang, S. H., Chien, C. M., Lin, Y. H., Hu, X. W., et al. ( 2007) Induction of G2/M phase arrest and apoptosis by a novel enediyne derivative, THDB, in chronic myeloid leukemia (HL-60) cells. Toxicol. In Vitro. 21, 9098.
  • 26
    Fujimoto, K., Hosotani, R., Doi, R., Wada, M., Lee, J. U., et al. ( 1999) Induction of cell-cycle arrest and apoptosis by a novel retinobenzoic-acid derivative, TAC-101, in human pancreatic-cancer cells. Int. J. Cancer 81, 637644.
  • 27
    King, K. L. and Cidlowski, J. A. ( 1998) Cell cycle regulation and apoptosis. Annu. Rev. Physiol. 60, 601617.
  • 28
    Nurse, P. ( 1990) Universal control mechanism regulating onset of M-phase. Nature 344, 503508.
  • 29
    Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., et al. ( 1993) p21 is a universal inhibitor of cyclin kinases. Nature 366, 701704.
  • 30
    Choi, Y. H., Lee, W. H., Park, K. Y., and Zhang, L. ( 2000) p53-Independent induction of p21 (WAF1/CIP1), reduction of cyclin B1 and G2/M arrest by the isoflavone genistein in human prostate carcinoma cells. Jpn. J. Cancer Res. 91, 164173.
  • 31
    Reed, J. C. ( 1998) Bcl-2 family proteins. Oncogene 17, 32253236.
  • 32
    Kluck, R. M., Bossy-Wetzel, E., Green, D. R., and Newmeyer, D. D. ( 1997) The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 275, 11321136.
  • 33
    Shimizu, S., Narita, M., and Tsujimoto, Y. ( 1999) Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature 399, 483487.
  • 34
    Wen, J., You, K. R., Lee, S. Y., Song, C. H., and Kim, D. G. ( 2002) Oxidative stress-mediated apoptosis. The anticancer effect of the sesquiterpene lactone parthenolide. J. Biol. Chem. 277, 3895438964.
  • 35
    Raitano, A. B., Whang, Y. E., and Sawyers, C. L. ( 1997) Signal transduction by wild-type and leukemogenic Abl proteins. Biochim. Biophys. Acta 1333, 201216.
  • 36
    Sánchez-García, I. and Martín-Zanca, D. ( 1997) Regulation of Bcl-2 gene expression by BCR-ABL is mediated by Ras. J. Mol. Biol. 267, 225228.
  • 37
    Brauer, K. M., Werth, D., von Schwarzenberg, K., Bringmann, A., Kanz, L., et al. ( 2007) BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells. Cancer Res. 67, 54895497.
  • 38
    Gottesman, M. M., Fojo, T., and Bates, S. E. ( 2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2, 4858.
  • 39
    Friedrich, K., Wieder, T., Von Haefen, C., Radetzki, S., Jänicke, R., et al. ( 2001) Overexpression of caspase-3 restores sensitivity for drug-induced apoptosis in breast cancer cell lines with acquired drug resistance. Oncogene 20, 27492760.
  • 40
    Johnstone, R. W., Cretney, E., and Smyth, M. J. ( 1999) P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood 93, 10751085.